3/17
04:43 pm
mygn
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer [Yahoo! Finance]
Medium
Report
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer [Yahoo! Finance]
3/17
04:05 pm
mygn
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Medium
Report
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
3/17
09:27 am
mygn
2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off [Yahoo! Finance]
Medium
Report
2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off [Yahoo! Finance]
3/12
08:21 am
mygn
Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer [Yahoo! Finance]
3/11
01:03 pm
mygn
3 Reasons to Sell MYGN and 1 Stock to Buy Instead [Yahoo! Finance]
Medium
Report
3 Reasons to Sell MYGN and 1 Stock to Buy Instead [Yahoo! Finance]
3/11
11:15 am
mygn
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc [Yahoo! Finance]
Low
Report
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc [Yahoo! Finance]
3/10
03:30 pm
mygn
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know [Yahoo! Finance]
Low
Report
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know [Yahoo! Finance]
3/6
08:31 am
mygn
2 Unprofitable Stocks on Our Buy List and 1 We Brush Off [Yahoo! Finance]
Low
Report
2 Unprofitable Stocks on Our Buy List and 1 We Brush Off [Yahoo! Finance]
3/3
05:19 pm
mygn
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why [Yahoo! Finance]
Low
Report
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why [Yahoo! Finance]
3/2
04:40 pm
mygn
Myriad Commercially Launches Precise MRD with Select Community Oncologists [Yahoo! Finance]
Medium
Report
Myriad Commercially Launches Precise MRD with Select Community Oncologists [Yahoo! Finance]
3/2
04:05 pm
mygn
Myriad Commercially Launches Precise MRD with Select Community Oncologists
Medium
Report
Myriad Commercially Launches Precise MRD with Select Community Oncologists
2/28
05:57 am
mygn
Myriad Genetics (MYGN) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
Myriad Genetics (MYGN) was upgraded by Zacks Research from "strong sell" to "hold".
2/24
11:31 am
mygn
Why Myriad Genetics (MYGN) Stock Is Trading Up Today [Yahoo! Finance]
Low
Report
Why Myriad Genetics (MYGN) Stock Is Trading Up Today [Yahoo! Finance]
2/24
10:18 am
mygn
Myriad Genetics (NASDAQ:MYGN) had its price target lowered by analysts at Wells Fargo & Company from $6.50 to $6.00. They now have an "equal weight" rating on the stock.
Medium
Report
Myriad Genetics (NASDAQ:MYGN) had its price target lowered by analysts at Wells Fargo & Company from $6.50 to $6.00. They now have an "equal weight" rating on the stock.
2/24
09:03 am
mygn
Myriad Genetics (NASDAQ:MYGN) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
High
Report
Myriad Genetics (NASDAQ:MYGN) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
2/24
09:00 am
mygn
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
High
Report
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
2/24
12:21 am
mygn
Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Highlights: Surpassing Revenue Expectations ... [Yahoo! Finance]
High
Report
Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Highlights: Surpassing Revenue Expectations ... [Yahoo! Finance]
2/23
04:31 pm
mygn
Myriad Genetics's (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22% [Yahoo! Finance]
High
Report
Myriad Genetics's (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22% [Yahoo! Finance]
2/23
04:05 pm
mygn
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
Low
Report
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
2/19
09:15 am
mygn
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
Low
Report
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
2/16
04:41 pm
mygn
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 [Yahoo! Finance]
Low
Report
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 [Yahoo! Finance]
2/16
04:15 pm
mygn
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Low
Report
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
1/27
08:50 am
mygn
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
Low
Report
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
1/22
04:00 am
mygn
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm [Yahoo! Finance]
Medium
Report
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm [Yahoo! Finance]
1/21
06:20 am
mygn
Myriad Genetics (NASDAQ:MYGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Myriad Genetics (NASDAQ:MYGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.